The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Several studies have been done on the myriad list of side effects that come from popular weight loss drugs.  A new study ...

Scientists are trying to tackle Alzheimer's from all angles, and a new study adds to the growing evidence that semaglutide, a ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

In the past year, treatments such as Wegovy, Mounjaro and Zepbound have become household names. But there are many questions ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

A new obesity 'wonder drug’ arrives on the Irish market today. The weight loss medication Wegovy, which is similar to Ozempic ...

Currently, Ozempic is only approved to treat type 2 diabetes. But in recent years, the semaglutide injection has become a ...